Professor Kang Chunsheng, the moderator of this forum, introduced and thanked the guests attending the forum, including Academician He Fuchu of the National Center for Protein Sciences (Beijing), Director Xu Ping of the Proteomics Committee of the Chinese Society of Biochemistry and Molecular Biology, Deputy Director Wang Shucai of the Medical Device Regulation Department of the National Medical Products Administration, and Deputy Director Xu Wei of the Center for Medical Device Evaluation.

At the start of the conference, Director Xu Ping extended a warm welcome and sincere thanks to the friends who participated in this forum and who care about the clinical development of proteomics, and said in his address: “Proteomics stands at the frontier of life science research and has made remarkable progress in recent years, most notably represented by the international big science program ‘Human Proteome Navigation’ (‘π-Hub Program’) initiated by Academician He Fuchu and other scientists, which has global influence. This program is actively promoting the comprehensive development of proteomics-related technologies, enabling faster and more accurate exploration of the important roles of proteins in life, and ultimately applying proteomics research results to all fields of clinical medicine to contribute to human health. While proteomics technology demonstrates its powerful functional advantages and is almost reaching the patient’s bedside, it faces issues such as being more complex and less stable than traditional clinical methodologies, and the road to ‘clinical admission’ requires crossing multiple key nodes similar to those experienced by genomics. These issues require our joint efforts, collective wisdom and a search for solutions. Through today’s conference, I hope we can pool our collective wisdom and strength to take a solid step toward promoting the clinical application of proteomics technology!”

Professor Guo Tiannan, Westlake University

Professor Guo Tiannan shared “Clinical Practice and Challenges of Proteomics in the Field of Thyroid Cancer.” Starting from the current development status of thyroid cancer, its global distribution and the advantages and disadvantages of various diagnostic methods, he expounded on the main research methods for determining the benign or malignant nature of thyroid nodules based on proteomics, the challenges faced in the research, and analyzed in detail the advantages compared with other methods.

Deputy Director Wang Shucai shared “Regulatory Requirements for Proteomics-related Products.” Starting from the development status of the in vitro diagnostics industry at home and abroad, the construction of regulations and systems related to in vitro diagnostic reagents, and how regulatory policies can be improved, he shared how to provide more efficient support for enterprises’ products to enter clinical use and jointly advance the development of medical devices.

Deputy Director Xu Wei gave a detailed introduction to “New Progress in the IVD Registration System.” From a policy perspective, he deeply interpreted the reform measures adopted in response to issues such as insufficient support for scientific and technological innovation in China’s drugs and medical devices and the gap between the quality of marketed products and advanced international levels, including reforming clinical trial management, accelerating marketing review and approval, strengthening full-lifecycle management and enhancing technical support capabilities; he also shared in detail the relevant concepts, guiding principles, policy channels, innovation review and patent authorization of IVD.

In his closing remarks, Academician He Fuchu fondly reviewed the path of exploration from genetics to proteomics, pointing out that proteomics, with its unique perspective and methods, takes on life science problems that genomics and transcriptomics struggle to answer, revealing new mechanisms such as cholesterol metabolism reprogramming that traditional omics cannot reach. He emphasized that the current state of proteomics is like “learning elementary school Chinese and arithmetic”—although elementary, it has already demonstrated powerful potential beyond traditional omics, and is the “poetry and distant place” of precision medicine.

Academician He stated that proteomics is not only the future of science, but also a key force for achieving mastery and great undertakings and for driving national and epochal progress. He called on all forces to join hearts and hands to jointly nurture this “ugly yet infinitely possible newborn”—proteomics—so that it can grow strong, achieve the brilliance of the “π-HuB Program,” and contribute to human health and the future of humanity.

The successful holding of the first special forum on “Clinical Admission of Proteomics” marks a solid step forward in the deep integration of proteomics and clinical practice. Just as Academician He firmly believes: I hope this conference becomes the “Jiaxing Meeting” for the clinical admission of proteomics, focused in heart and innovative in action. Let all colleagues in the industry join hands to march toward the “poetry and distant place” of proteomics.